Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 23 entries
Sorted by: Best Match Show Resources per page
Introduction of the Carotenoid Biosynthesis α-Branch Into .

Frontiers in plant science

Lehmann M, Vamvaka E, Torrado A, Jahns P, Dann M, Rosenhammer L, Aziba A, Leister D, Rühle T.
PMID: 34295345
Front Plant Sci. 2021 Jul 06;12:699424. doi: 10.3389/fpls.2021.699424. eCollection 2021.

Lutein, made by the α-branch of the methyl-erythritol phosphate (MEP) pathway, is one of the most abundant xanthophylls in plants. It is involved in the structural stabilization of light-harvesting complexes, transfer of excitation energy to chlorophylls and photoprotection. In...

Cite
Lehmann M, Vamvaka E, Torrado A, et al. Introduction of the Carotenoid Biosynthesis α-Branch Into . Front Plant Sci. 2021;12:699424doi: 10.3389/fpls.2021.699424.
Lehmann, M., Vamvaka, E., Torrado, A., Jahns, P., Dann, M., Rosenhammer, L., Aziba, A., Leister, D., & Rühle, T. (2021). Introduction of the Carotenoid Biosynthesis α-Branch Into . Frontiers in plant science, 12699424. https://doi.org/10.3389/fpls.2021.699424
Lehmann, Martin, et al. "Introduction of the Carotenoid Biosynthesis α-Branch Into ." Frontiers in plant science vol. 12 (2021): 699424. doi: https://doi.org/10.3389/fpls.2021.699424
Lehmann M, Vamvaka E, Torrado A, Jahns P, Dann M, Rosenhammer L, Aziba A, Leister D, Rühle T. Introduction of the Carotenoid Biosynthesis α-Branch Into . Front Plant Sci. 2021 Jul 06;12:699424. doi: 10.3389/fpls.2021.699424. eCollection 2021. PMID: 34295345; PMCID: PMC8291087.
Copy Download .nbib Format: NLM
Applications of Therapeutic Apheresis in Patients with Malignant Disease.

The oncologist

Pineda AA, Vamvakas EC.
PMID: 10388036
Oncologist. 1997;2(2):94-103.

Therapeutic apheresis (TA) provides the means for the removal of blood components that are abnormal or that circulate in excessive amounts and have a defined pathogenetic role, or are thought to have one. Multiple disease processes have been treated...

Cite
Pineda AA, Vamvakas EC. Applications of Therapeutic Apheresis in Patients with Malignant Disease. Oncologist. 1997;2(2):94-103
Pineda, A. A., & Vamvakas, E. C. (1997). Applications of Therapeutic Apheresis in Patients with Malignant Disease. The oncologist, 2(2), 94-103.
Pineda, and Vamvakas. "Applications of Therapeutic Apheresis in Patients with Malignant Disease." The oncologist vol. 2,2 (1997): 94-103.
Pineda AA, Vamvakas EC. Applications of Therapeutic Apheresis in Patients with Malignant Disease. Oncologist. 1997;2(2):94-103. PMID: 10388036.
Copy Download .nbib Format: NLM
Tubular Carcinoma of the Breast: Immunohistochemical and DNA Flow Cytometric Profile.

The breast journal

Fasano M, Vamvakas E, Delgado Y, Inghirami G, Mitnick J, Roses D, Feiner H.
PMID: 11348296
Breast J. 1999 Jul;5(4):252-255. doi: 10.1046/j.1524-4741.1999.98103.x.

Molecular markers of ordinary invasive ductal carcinoma of the breast have been extensively studied and their prognostic significance has been assessed. A common variant of breast cancer, tubular carcinoma, has an excellent prognosis as judged from several clinicopathologic studies....

Cite
Fasano M, Vamvakas E, Delgado Y, et al. Tubular Carcinoma of the Breast: Immunohistochemical and DNA Flow Cytometric Profile. Breast J. 1999;5(4):252-255doi: 10.1046/j.1524-4741.1999.98103.x.
Fasano, M., Vamvakas, E., Delgado, Y., Inghirami, G., Mitnick, J., Roses, D., & Feiner, H. (1999). Tubular Carcinoma of the Breast: Immunohistochemical and DNA Flow Cytometric Profile. The breast journal, 5(4), 252-255. https://doi.org/10.1046/j.1524-4741.1999.98103.x
Fasano, Maria, et al. "Tubular Carcinoma of the Breast: Immunohistochemical and DNA Flow Cytometric Profile." The breast journal vol. 5,4 (1999): 252-255. doi: https://doi.org/10.1046/j.1524-4741.1999.98103.x
Fasano M, Vamvakas E, Delgado Y, Inghirami G, Mitnick J, Roses D, Feiner H. Tubular Carcinoma of the Breast: Immunohistochemical and DNA Flow Cytometric Profile. Breast J. 1999 Jul;5(4):252-255. doi: 10.1046/j.1524-4741.1999.98103.x. PMID: 11348296.
Copy Download .nbib Format: NLM
INTERSTAARS: Attention training for infants with elevated likelihood of developing ADHD: A proof-of-concept randomised controlled trial.

Translational psychiatry

Goodwin A, Jones EJH, Salomone S, Mason L, Holman R, Begum-Ali J, Hunt A, Ruddock M, Vamvakas G, Robinson E, Holden CJ, Taylor C, Smith TJ, Sonuga-Barke E, Bolton P, Charman T, Pickles A, Wass S, Johnson MH.
PMID: 34930893
Transl Psychiatry. 2021 Dec 20;11(1):644. doi: 10.1038/s41398-021-01698-9.

Attention-deficit/hyperactivity disorder (ADHD) is first diagnosed during middle childhood, when patterns of difficulty are often established. Pre-emptive approaches that strengthen developing cognitive systems could offer an alternative to post-diagnostic interventions. This proof-of-concept randomised controlled trial (RCT) tested whether computerised...

Cite
Goodwin A, Jones EJH, Salomone S, et al. INTERSTAARS: Attention training for infants with elevated likelihood of developing ADHD: A proof-of-concept randomised controlled trial. Transl Psychiatry. 2021;11(1):644doi: 10.1038/s41398-021-01698-9.
Goodwin, A., Jones, E. J. H., Salomone, S., Mason, L., Holman, R., Begum-Ali, J., Hunt, A., Ruddock, M., Vamvakas, G., Robinson, E., Holden, C. J., Taylor, C., Smith, T. J., Sonuga-Barke, E., Bolton, P., Charman, T., Pickles, A., Wass, S., Johnson, M. H. (2021). INTERSTAARS: Attention training for infants with elevated likelihood of developing ADHD: A proof-of-concept randomised controlled trial. Translational psychiatry, 11(1), 644. https://doi.org/10.1038/s41398-021-01698-9
Goodwin, Amy, et al. "INTERSTAARS: Attention training for infants with elevated likelihood of developing ADHD: A proof-of-concept randomised controlled trial." Translational psychiatry vol. 11,1 (2021): 644. doi: https://doi.org/10.1038/s41398-021-01698-9
Goodwin A, Jones EJH, Salomone S, Mason L, Holman R, Begum-Ali J, Hunt A, Ruddock M, Vamvakas G, Robinson E, Holden CJ, Taylor C, Smith TJ, Sonuga-Barke E, Bolton P, Charman T, Pickles A, Wass S, Johnson MH. INTERSTAARS: Attention training for infants with elevated likelihood of developing ADHD: A proof-of-concept randomised controlled trial. Transl Psychiatry. 2021 Dec 20;11(1):644. doi: 10.1038/s41398-021-01698-9. PMID: 34930893.
Copy Download .nbib Format: NLM
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease.

Journal of Parkinson's disease

Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, Conrado DJ, Dexter DT, Seibyl J, Jennings D, Nicholas T, Matthews D, Xie Z, Imam S, Maguire P, Russell D, Gordon MF, Stebbins GT, Somer E, Gallagher J, Roach A, Basseches P, Grosset D, Marek K.
PMID: 31524182
J Parkinsons Dis. 2019;9(4):825. doi: 10.3233/JPD-199003.

No abstract available.

Cite
Stephenson D, Hill D, Cedarbaum JM, et al. The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease. J Parkinsons Dis. 2019;9(4):825doi: 10.3233/JPD-199003.
Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., Nicholas, T., Matthews, D., Xie, Z., Imam, S., Maguire, P., Russell, D., Gordon, M. F., Stebbins, G. T., Somer, E., Gallagher, J., Roach, A., Basseches, P., Grosset, D., Marek, K. (2019). The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease. Journal of Parkinson's disease, 9(4), 825. https://doi.org/10.3233/JPD-199003
Stephenson, Diane, et al. "The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease." Journal of Parkinson's disease vol. 9,4 (2019): 825. doi: https://doi.org/10.3233/JPD-199003
Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, Conrado DJ, Dexter DT, Seibyl J, Jennings D, Nicholas T, Matthews D, Xie Z, Imam S, Maguire P, Russell D, Gordon MF, Stebbins GT, Somer E, Gallagher J, Roach A, Basseches P, Grosset D, Marek K. The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease. J Parkinsons Dis. 2019;9(4):825. doi: 10.3233/JPD-199003. PMID: 31524182; PMCID: PMC6878913.
Copy Download .nbib Format: NLM
Cancer in end-stage renal disease: potential factors involved -editorial-.

American journal of nephrology

Vamvakas S, Bahner U, Heidland A.
PMID: 9569948
Am J Nephrol. 1998;18(2):89-95. doi: 10.1159/000013314.

Increased incidence of cancer at various sites is observed in patients with end-stage renal disease (ESRD). In particular, lymphomas and carcinomas of the kidney, prostate, liver and uterus show an enhanced prevalence in these subjects compared with the general...

Cite
Vamvakas S, Bahner U, Heidland A. Cancer in end-stage renal disease: potential factors involved -editorial-. Am J Nephrol. 1998;18(2):89-95doi: 10.1159/000013314.
Vamvakas, S., Bahner, U., & Heidland, A. (1998). Cancer in end-stage renal disease: potential factors involved -editorial-. American journal of nephrology, 18(2), 89-95. https://doi.org/10.1159/000013314
Vamvakas, S, et al. "Cancer in end-stage renal disease: potential factors involved -editorial-." American journal of nephrology vol. 18,2 (1998): 89-95. doi: https://doi.org/10.1159/000013314
Vamvakas S, Bahner U, Heidland A. Cancer in end-stage renal disease: potential factors involved -editorial-. Am J Nephrol. 1998;18(2):89-95. doi: 10.1159/000013314. PMID: 9569948.
Copy Download .nbib Format: NLM
Two-stage sampling in the estimation of growth parameters and percentile norms: sample weights versus auxiliary variable estimation.

BMC medical research methodology

Vamvakas G, Norbury C, Pickles A.
PMID: 34404347
BMC Med Res Methodol. 2021 Aug 17;21(1):173. doi: 10.1186/s12874-021-01353-3.

BACKGROUND: The use of auxiliary variables with maximum likelihood parameter estimation for surveys that miss data by design is not a widespread approach, despite its documented improved efficiency over traditional approaches that deploy sampling weights. Although efficiency gains from...

Cite
Vamvakas G, Norbury C, Pickles A. Two-stage sampling in the estimation of growth parameters and percentile norms: sample weights versus auxiliary variable estimation. BMC Med Res Methodol. 2021;21(1):173doi: 10.1186/s12874-021-01353-3.
Vamvakas, G., Norbury, C., & Pickles, A. (2021). Two-stage sampling in the estimation of growth parameters and percentile norms: sample weights versus auxiliary variable estimation. BMC medical research methodology, 21(1), 173. https://doi.org/10.1186/s12874-021-01353-3
Vamvakas, George, et al. "Two-stage sampling in the estimation of growth parameters and percentile norms: sample weights versus auxiliary variable estimation." BMC medical research methodology vol. 21,1 (2021): 173. doi: https://doi.org/10.1186/s12874-021-01353-3
Vamvakas G, Norbury C, Pickles A. Two-stage sampling in the estimation of growth parameters and percentile norms: sample weights versus auxiliary variable estimation. BMC Med Res Methodol. 2021 Aug 17;21(1):173. doi: 10.1186/s12874-021-01353-3. PMID: 34404347; PMCID: PMC8369688.
Copy Download .nbib Format: NLM
INTERSTAARS: Attention training for infants with elevated likelihood of developing ADHD: A proof-of-concept randomised controlled trial.

Translational psychiatry

Goodwin A, Jones EJH, Salomone S, Mason L, Holman R, Begum-Ali J, Hunt A, Ruddock M, Vamvakas G, Robinson E, Holden CJ, Taylor C, Smith TJ, Sonuga-Barke E, Bolton P, Charman T, Pickles A, Wass S, Johnson MH.
PMID: 34930893
Transl Psychiatry. 2021 Dec 20;11(1):644. doi: 10.1038/s41398-021-01698-9.

Attention-deficit/hyperactivity disorder (ADHD) is first diagnosed during middle childhood, when patterns of difficulty are often established. Pre-emptive approaches that strengthen developing cognitive systems could offer an alternative to post-diagnostic interventions. This proof-of-concept randomised controlled trial (RCT) tested whether computerised...

Cite
Goodwin A, Jones EJH, Salomone S, et al. INTERSTAARS: Attention training for infants with elevated likelihood of developing ADHD: A proof-of-concept randomised controlled trial. Transl Psychiatry. 2021;11(1):644doi: 10.1038/s41398-021-01698-9.
Goodwin, A., Jones, E. J. H., Salomone, S., Mason, L., Holman, R., Begum-Ali, J., Hunt, A., Ruddock, M., Vamvakas, G., Robinson, E., Holden, C. J., Taylor, C., Smith, T. J., Sonuga-Barke, E., Bolton, P., Charman, T., Pickles, A., Wass, S., Johnson, M. H. (2021). INTERSTAARS: Attention training for infants with elevated likelihood of developing ADHD: A proof-of-concept randomised controlled trial. Translational psychiatry, 11(1), 644. https://doi.org/10.1038/s41398-021-01698-9
Goodwin, Amy, et al. "INTERSTAARS: Attention training for infants with elevated likelihood of developing ADHD: A proof-of-concept randomised controlled trial." Translational psychiatry vol. 11,1 (2021): 644. doi: https://doi.org/10.1038/s41398-021-01698-9
Goodwin A, Jones EJH, Salomone S, Mason L, Holman R, Begum-Ali J, Hunt A, Ruddock M, Vamvakas G, Robinson E, Holden CJ, Taylor C, Smith TJ, Sonuga-Barke E, Bolton P, Charman T, Pickles A, Wass S, Johnson MH. INTERSTAARS: Attention training for infants with elevated likelihood of developing ADHD: A proof-of-concept randomised controlled trial. Transl Psychiatry. 2021 Dec 20;11(1):644. doi: 10.1038/s41398-021-01698-9. PMID: 34930893; PMCID: PMC8688472.
Copy Download .nbib Format: NLM
Toward a patient-based paradigm for blood transfusion.

Journal of blood medicine

Farrugia A, Vamvakas E.
PMID: 24520208
J Blood Med. 2014 Jan 31;5:5-13. doi: 10.2147/JBM.S55769. eCollection 2014.

The current "manufacturing paradigm" of transfusion practice has detached transfusion from the clinical environment. As an example, fresh whole blood in large-volume hemorrhage may be superior to whole blood reconstituted from multiple components. Multicomponent apheresis can overcome logistical difficulties...

Cite
Farrugia A, Vamvakas E. Toward a patient-based paradigm for blood transfusion. J Blood Med. 2014;5:5-13doi: 10.2147/JBM.S55769.
Farrugia, A., & Vamvakas, E. (2014). Toward a patient-based paradigm for blood transfusion. Journal of blood medicine, 55-13. https://doi.org/10.2147/JBM.S55769
Farrugia, Albert, and Vamvakas, Eleftherios. "Toward a patient-based paradigm for blood transfusion." Journal of blood medicine vol. 5 (2014): 5-13. doi: https://doi.org/10.2147/JBM.S55769
Farrugia A, Vamvakas E. Toward a patient-based paradigm for blood transfusion. J Blood Med. 2014 Jan 31;5:5-13. doi: 10.2147/JBM.S55769. eCollection 2014. PMID: 24520208; PMCID: PMC3917954.
Copy Download .nbib Format: NLM
Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.

Frontiers in medicine

Farkas AM, Mariz S, Stoyanova-Beninska V, Celis P, Vamvakas S, Larsson K, Sepodes B.
PMID: 28560211
Front Med (Lausanne). 2017 May 16;4:53. doi: 10.3389/fmed.2017.00053. eCollection 2017.

In 2008, the European Union introduced the Advanced Medicines Regulation aiming to improve regulation of advanced therapy medicinal products (ATMPs). We applied the ATMPs classification definitions in this Regulation to understand the link of this emerging group of medicinal...

Cite
Farkas AM, Mariz S, Stoyanova-Beninska V, et al. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe. Front Med (Lausanne). 2017;4:53doi: 10.3389/fmed.2017.00053.
Farkas, A. M., Mariz, S., Stoyanova-Beninska, V., Celis, P., Vamvakas, S., Larsson, K., & Sepodes, B. (2017). Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe. Frontiers in medicine, 453. https://doi.org/10.3389/fmed.2017.00053
Farkas, Andreas M, et al. "Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe." Frontiers in medicine vol. 4 (2017): 53. doi: https://doi.org/10.3389/fmed.2017.00053
Farkas AM, Mariz S, Stoyanova-Beninska V, Celis P, Vamvakas S, Larsson K, Sepodes B. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe. Front Med (Lausanne). 2017 May 16;4:53. doi: 10.3389/fmed.2017.00053. eCollection 2017. PMID: 28560211; PMCID: PMC5432638.
Copy Download .nbib Format: NLM
Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study.

Translational lung cancer research

Rounis K, Makrakis D, Tsigkas AP, Georgiou A, Galanakis N, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Vardakis N, Kontogianni M, Gioulbasanis I, Mavroudis D, Agelaki S.
PMID: 34584855
Transl Lung Cancer Res. 2021 Aug;10(8):3538-3549. doi: 10.21037/tlcr-21-460.

BACKGROUND: Cancer cachexia syndrome (CCS) is an adverse prognostic factor in cancer patients undergoing chemotherapy or surgical procedures. We performed a prospective study to investigate the effect of CCS on treatment outcomes in patients with non-oncogene driven metastatic non-small...

Cite
Rounis K, Makrakis D, Tsigkas AP, et al. Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. Transl Lung Cancer Res. 2021;10(8):3538-3549doi: 10.21037/tlcr-21-460.
Rounis, K., Makrakis, D., Tsigkas, A. P., Georgiou, A., Galanakis, N., Papadaki, C., Monastirioti, A., Vamvakas, L., Kalbakis, K., Vardakis, N., Kontogianni, M., Gioulbasanis, I., Mavroudis, D., & Agelaki, S. (2021). Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. Translational lung cancer research, 10(8), 3538-3549. https://doi.org/10.21037/tlcr-21-460
Rounis, Konstantinos, et al. "Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study." Translational lung cancer research vol. 10,8 (2021): 3538-3549. doi: https://doi.org/10.21037/tlcr-21-460
Rounis K, Makrakis D, Tsigkas AP, Georgiou A, Galanakis N, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Vardakis N, Kontogianni M, Gioulbasanis I, Mavroudis D, Agelaki S. Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study. Transl Lung Cancer Res. 2021 Aug;10(8):3538-3549. doi: 10.21037/tlcr-21-460. PMID: 34584855; PMCID: PMC8435387.
Copy Download .nbib Format: NLM
Genotoxicity of haloalkene and haloalkane glutathione S-conjugates in porcine kidney cells.

Toxicology in vitro : an international journal published in association with BIBRA

Vamvakas S, Dekant W, Henschler D.
PMID: 20702313
Toxicol In Vitro. 1989;3(2):151-6. doi: 10.1016/0887-2333(89)90058-1.

The genotoxicity of the glutathione S-conjugates S-(12-dichlorovinyl)glutathione (DCVG), S-(1,2,2-trichlorovinyl)glutathione (TCVG), S-(1,2,3,4,4-pentachlorobutadienyl)glutathione (PCBG) and S-(2-chloroethyl)glutathione (CEG) was investigated in LLC-PK1, a cultured line of porcine kidney cells that exhibits many properties of proximal tubular cells. DNA damage caused by treatment...

Cite
Vamvakas S, Dekant W, Henschler D. Genotoxicity of haloalkene and haloalkane glutathione S-conjugates in porcine kidney cells. Toxicol In Vitro. 1989;3(2):151-6doi: 10.1016/0887-2333(89)90058-1.
Vamvakas, S., Dekant, W., & Henschler, D. (1989). Genotoxicity of haloalkene and haloalkane glutathione S-conjugates in porcine kidney cells. Toxicology in vitro : an international journal published in association with BIBRA, 3(2), 151-6. https://doi.org/10.1016/0887-2333(89)90058-1
Vamvakas, S, et al. "Genotoxicity of haloalkene and haloalkane glutathione S-conjugates in porcine kidney cells." Toxicology in vitro : an international journal published in association with BIBRA vol. 3,2 (1989): 151-6. doi: https://doi.org/10.1016/0887-2333(89)90058-1
Vamvakas S, Dekant W, Henschler D. Genotoxicity of haloalkene and haloalkane glutathione S-conjugates in porcine kidney cells. Toxicol In Vitro. 1989;3(2):151-6. doi: 10.1016/0887-2333(89)90058-1. PMID: 20702313.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 23 entries